Want to see COR full AI Analyst Report?
COR Stock Chart & Stats
$328.06
$1.26(0.41%)
At close: 4:00 PM EDT
$328.06
$1.26(0.41%)
Day’s Range― - ―
52-Week Range$244.82 - $377.54
Previous Close$311.15
Volume1.00M
Average Volume (3M)1.24M
Market Cap
$65.06B
Enterprise Value$63.93B
Total Cash (Recent Filing)$2.82B
Total Debt (Recent Filing)$11.72B
Price to Earnings (P/E)25.2
Beta0.08
Next Earnings
Nov 04, 2026EPS Estimate
4.58Next Dividend Ex-DateN/A
Dividend Yield0.7%
Share Statistics
EPS (TTM)13.52
Shares Outstanding190,827,160
10 Day Avg. Volume1,153,500
30 Day Avg. Volume1,241,227
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda12.42
Forecast
1Y Price Target
$368.25Price Target Upside12.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)19.76
Revenue Forecast (FY)$352.05B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationCencora’s substantial free cash flow gives the business internal funding capacity for operations, investment, and debt service. Although conversion varies with working capital, the absolute cash generation strengthens financial flexibility and supports resilience over the coming quarters.
Specialty-led Margin ExpansionSpecialty exposure and the OneOncology acquisition are improving gross profit and expanding margins beyond the company’s historically thin distributor economics. If specialty demand and integration benefits persist, this mix shift can support stronger earnings quality and operating leverage.
Improving Operating ExecutionRaised operating income and adjusted EPS guidance indicates management is converting segment growth into improved profitability despite identified headwinds. Stronger U.S. Healthcare Solutions, International, and specialty execution provides a durable earnings foundation over the next several quarters.
Bears Say
Elevated Balance-sheet LeverageHigh leverage relative to equity leaves Cencora more sensitive to working-capital swings, financing costs, and capital allocation decisions. While equity has rebuilt, the historical weakness and current debt burden reduce balance-sheet resilience if operating conditions deteriorate.
Structurally Thin MarginsCencora’s distribution model produces large revenue but limited percentage margins, leaving relatively little earnings cushion when pricing or volumes weaken. This structurally narrow margin profile can make modest operational pressure more consequential for profitability and cash conversion.
Potential MWI Transaction Earnings DragThe contemplated MWI-Covetrus transaction could reduce Other segment operating income and fiscal 2027 earnings if it closes as described. Although transaction proceeds may partly offset the impact, the deal introduces a concrete integration and earnings headwind beyond normal operations.
Cencora News
COR FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was $244.82 and its highest was $377.54 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is $65.06B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Nov 04, 2026 which is in 16 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on Aug 05, 2026. The company reported $4.48 earnings per share for the quarter, beating the consensus estimate of $4.347 by $0.133.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.7%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 4.58.
How many shares outstanding does Cencora have?
Cencora has 190,827,160 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of $4.48 in its last earnings report, beating expectations of $4.347. Following the earnings report the stock price went up 3.572%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in COR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$368.25 (12.25% Upside)
$368.25 (12.25% Upside)
Blogger Sentiment
Bullish
COR Sentiment 80%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 21.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.55%
12-Months-Change
Fundamentals
Return on Equity
106.43%
Trailing 12-Months
Asset Growth
13.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cencora
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution and durable specialty-driven growth: consolidated revenue and adjusted gross profit growth, margin expansion, double-digit operating income increases, 12% EPS growth, upgraded EPS guidance, significant share repurchases, and robust free cash flow. Key drivers included strong U.S. Healthcare Solutions performance (MSOs and specialty), International momentum, and OneOncology outperforming expectations. Headwinds discussed were notable but largely manageable: $2.4B of manufacturer list-price reductions, a prior oncology customer loss, lower mail-order sales, acquisition-related higher operating expenses and increased interest expense, and a potential FY27 earnings headwind from the planned MWI transaction. Overall, the positive operational and financial outcomes and guidance raise outweigh the discrete and partly acquisition-related challenges.View all COR earnings summariesCOR Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations

COR Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$368.25
▲(12.25% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Cardinal Health
―
Henry Schein
―
McKesson
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
0.19% Insiders
31.40% Mutual Funds
1.06% Other Institutional Investors
38.80% Public Companies and Individual Investors












